Article info
PDFCommentary
Devaluation of persons by biotechnology-facilitated practices at the beginning and at the end of life
- Correspondence to Dr Bjørn Hofmann, Centre for Medical Ethics, University of Oslo, 0315 Oslo, Norway; b.m.hofmann{at}medisin.uio.no
Citation
Devaluation of persons by biotechnology-facilitated practices at the beginning and at the end of life
Publication history
- Received May 27, 2020
- Accepted June 3, 2020
- First published July 14, 2020.
Online issue publication
July 23, 2020
Article Versions
- Previous version (23 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Expressivism at the beginning and end of life
- Commentary on ‘expressivism at the beginning and end of life’
- Response to commentaries on ‘Expressivism at the beginning and end of life’
- Reed on expressivism at the end of life: a bridge too far
- Expressivism at the beginning and end of life
- Hostile environments? Down’s syndrome and genetic screening in contemporary culture
- An autonomy-based approach to assisted suicide: a way to avoid the expressivist objection against assisted dying laws
- The case for physician assisted suicide: how can it possibly be proven?
- The case for physician assisted suicide: not (yet) proven
- Prenatal diagnosis and selective abortion: a result of the cultural turn?